Intellia Therapeutics Inc (0JBU)

London
Currency in USD
9.79
-14.96(-60.44%)
Closed

0JBU Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa43.157.9933.0552.1236.28
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+41.63%+34.55%-43.01%+57.69%-30.4%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa108.41150.41229.81419.98435.07
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-65.31-92.41-196.75-367.86-398.79
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-11.3%-41.5%-112.9%-86.96%-8.41%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-151.52%-159.35%-595.27%-705.78%-1,099.36%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa41.0644.1771.190.31116.5
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-106.37-136.58-267.85-458.16-515.29
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-17.06%-28.41%-96.11%-71.05%-12.47%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-246.78%-235.51%-810.37%-879.04%-1,420.51%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa6.842.351.288.5449.83
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+23.67%-65.59%-45.45%+565.78%+483.38%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa6.842.351.288.5449.83
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa---1.33-11.08-15.63
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-99.53-134.23-267.89-460.7-481.09
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa----13.49-0.1
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-99.53-134.23-267.89-474.19-481.19
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-16.63%-34.86%-99.58%-77.01%-1.48%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-230.92%-231.46%-810.49%-909.78%-1,326.51%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-99.53-134.23-267.89-474.19-481.19
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-99.53-134.23-267.89-474.19-481.19
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-16.63%-34.86%-99.58%-77.01%-1.48%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-230.92%-231.46%-810.49%-909.78%-1,326.51%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-99.53-134.23-267.89-474.19-481.19
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.11-2.4-3.78-6.16-5.42
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-6.31%-13.81%-57.61%-63.03%+12.01%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.11-2.4-3.78-6.16-5.42
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-6.31%-13.81%-57.61%-63.03%+12.01%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa47.2555.9970.8976.9788.77
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa47.2555.9970.8976.9788.77
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-100.78-130.27-260.96-450.59-506.32
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-16.64%-29.26%-100.32%-72.67%-12.37%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-233.81%-224.63%-789.52%-864.51%-1,395.77%
EBIT
aa.aaaa.aaaa.aaaa.aa